Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

CA002-001

54 evidence topics · 5 sources

Objective
Location and study date
Registry status, dates, and sites
Study characteristicQuoted record
Protocol number“CA002-001”
Sponsor“Bristol-Myers Squibb”
Overall status“Terminated”
Reason stopped“(Non-safety reason, business objectives have changed)”
Study start“2013-11”
Primary completion“2016-03”
Study completion“2016-03”
United States site“Usc/Norris Comprehensive Cancer Center”
Site cities“Los Angeles”; “Parkville”; “Vancouver”; “Toronto”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse events of all grades by dose level
Adverse event1.2 mg once daily (N = 6)1.5 mg once daily (N = 7)Arm A total (N = 24)All patients (N = 36)
Diarrhoea“6 (100)”View highlighted excerpt for this quote“6 (86)”View highlighted excerpt for this quote“18 (75)”View highlighted excerpt for this quote“26 (72)”View highlighted excerpt for this quote
Nausea“4 (67)”View highlighted excerpt for this quote“5 (71)”View highlighted excerpt for this quote“15 (63)”View highlighted excerpt for this quote“22 (61)”View highlighted excerpt for this quote
Vomiting“2 (33)”View highlighted excerpt for this quote“4 (57)”View highlighted excerpt for this quote“12 (50)”View highlighted excerpt for this quote“16 (44)”View highlighted excerpt for this quote
Hypophosphataemia“6 (100)”View highlighted excerpt for this quote“4 (57)”View highlighted excerpt for this quote“16 (67)”View highlighted excerpt for this quote“23 (64)”View highlighted excerpt for this quote
Decreased appetite“2 (33)”View highlighted excerpt for this quote“1 (14)”View highlighted excerpt for this quote“8 (33)”View highlighted excerpt for this quote“13 (36)”View highlighted excerpt for this quote
Hypokalaemia“3 (50)”View highlighted excerpt for this quote“2 (29)”View highlighted excerpt for this quote“7 (29)”View highlighted excerpt for this quote“10 (28)”View highlighted excerpt for this quote
Rash“3 (50)”View highlighted excerpt for this quote“2 (29)”View highlighted excerpt for this quote“8 (33)”View highlighted excerpt for this quote“11 (31)”View highlighted excerpt for this quote
Pruritus“0”View highlighted excerpt for this quote“2 (29)”View highlighted excerpt for this quote“6 (25)”View highlighted excerpt for this quote“9 (25)”View highlighted excerpt for this quote
Fatigue“2 (33)”View highlighted excerpt for this quote“4 (57)”View highlighted excerpt for this quote“10 (42)”View highlighted excerpt for this quote“16 (44)”View highlighted excerpt for this quote
Study limitations
Summary
  • CA002-001 was an open-label, nonrandomized phase 1 dose-escalation study without a comparator arm in 36 participants with advanced solid tumours (24 in the once-daily arm and 12 in the twice-weekly arm). One participant (3%) had desmoid fibromatosis, so the study provides no estimate of efficacy in desmoid tumors; that participant “did not have documented disease progression before study entry” and was treated at 1.5 mg once daily, a dose above the 1.2 mg once-daily dose used in RINGSIDE.
  • Six participants received 1.2 mg once daily, and five of them were evaluable for dose-limiting toxicity. The median duration of treatment was 5.6 weeks (range 0.9 to 57.9 weeks), which limits the assessment of adverse events that emerge with longer exposure.
  • The study was “terminated early for business reasons”, and the maximum tolerated dose of the twice-weekly schedule was not established. The registry lists the reason as a “Non-safety reason, business objectives have changed” and shows no posted results.
  • Tumour response was assessed by the investigator per RECIST 1.1, with no central review reported. All analyses were descriptive.
  • The eligibility criteria required ECOG performance status 0 to 1, and the baseline characteristics report one participant (3%) with baseline WHO performance status 2.
  • Bristol-Myers Squibb sponsored and funded the study, and six authors were Bristol-Myers Squibb employees and stockholders.